Hye Ryoung Koo1,2, Jeong Seon Park2, Keon Wook Kang3, Wonshik Han4, In Ae Park5, Woo Kyung Moon6. 1. Department of Radiology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea. 2. Department of Radiology, Hanyang University College of Medicine, Seoul, Korea. 3. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 5. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Radiology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea. moonwk@snu.ac.kr.
Abstract
OBJECTIVES: The purpose of this study was to investigate whether a correlation exists between (18)F-fluorodeoxyglucose (FDG) uptake and prognostic factors in triple-negative breast cancer (TNBC). METHODS: Between January 2009 and December 2013, 103 patients (mean age, 50.6 years) with primary TNBC (mean, 2.6 cm; range, 1.0-6.5 cm) underwent (18)F-FDG PET/CT for initial staging. Correlations between maximum standardized uptake value (SUVmax) on PET/CT and prognostic factors including tumour size, nodal status, histological grade, Ki-67 proliferation index, tumour suppressor p53, and 'basal-like' markers (epidermal growth factor receptor and CK 5/6) were assessed. RESULTS: The mean SUVmax of the 103 tumours was 10.94 ± 5.25 (range: 2-32.8). There was a positive correlation between SUVmax and Ki-67 (Spearman's rho = 0.29, P = 0.003) and tumour size (Spearman's rho = 0.27, P = 0.006), whereas this relationship was not observed in the nodal status, histological grade, p53 status and 'basal-like' phenotypes. In a multivariate regression analysis, Ki-67 (P < 0.001) and tumour size (P = 0.009) were significantly associated with SUVmax in TNBCs. CONCLUSIONS: Increased (18)F-FDG uptake on PET/CT was correlated with a high Ki-67 proliferation index and larger tumour size in TNBC. These results suggest a potential role of (18)F-FDG PET/CT in identifying TNBC with more aggressive behaviour. KEY POINTS: • A wide range of FDG uptake reflected heterogeneity of cancer metabolism. • FDG uptake was correlated with the Ki-67 proliferation index in TNBC. • FDG uptake was correlated with tumour size in TNBC. • FDG uptake was not correlated with 'basal-like' phenotype.
OBJECTIVES: The purpose of this study was to investigate whether a correlation exists between (18)F-fluorodeoxyglucose (FDG) uptake and prognostic factors in triple-negative breast cancer (TNBC). METHODS: Between January 2009 and December 2013, 103 patients (mean age, 50.6 years) with primary TNBC (mean, 2.6 cm; range, 1.0-6.5 cm) underwent (18)F-FDG PET/CT for initial staging. Correlations between maximum standardized uptake value (SUVmax) on PET/CT and prognostic factors including tumour size, nodal status, histological grade, Ki-67 proliferation index, tumour suppressor p53, and 'basal-like' markers (epidermal growth factor receptor and CK 5/6) were assessed. RESULTS: The mean SUVmax of the 103 tumours was 10.94 ± 5.25 (range: 2-32.8). There was a positive correlation between SUVmax and Ki-67 (Spearman's rho = 0.29, P = 0.003) and tumour size (Spearman's rho = 0.27, P = 0.006), whereas this relationship was not observed in the nodal status, histological grade, p53 status and 'basal-like' phenotypes. In a multivariate regression analysis, Ki-67 (P < 0.001) and tumour size (P = 0.009) were significantly associated with SUVmax in TNBCs. CONCLUSIONS: Increased (18)F-FDG uptake on PET/CT was correlated with a high Ki-67 proliferation index and larger tumour size in TNBC. These results suggest a potential role of (18)F-FDG PET/CT in identifying TNBC with more aggressive behaviour. KEY POINTS: • A wide range of FDG uptake reflected heterogeneity of cancer metabolism. • FDG uptake was correlated with the Ki-67 proliferation index in TNBC. • FDG uptake was correlated with tumour size in TNBC. • FDG uptake was not correlated with 'basal-like' phenotype.
Entities:
Keywords:
18F-FDG PET/CT; Cancer metabolism; Immunohistochemistry; Ki-67 proliferation index; Triple-negative breast cancer
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Mathieu Hatt; David Groheux; Antoine Martineau; Marc Espié; Elif Hindié; Sylvie Giacchetti; Anne de Roquancourt; Dimitris Visvikis; Catherine Cheze-Le Rest Journal: J Nucl Med Date: 2013-01-17 Impact factor: 10.057
Authors: Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Nariya Cho; Jung Min Chang; Min Sun Bae; Won Hwa Kim; Su Hyun Lee; Mi Young Kim; Jin You Kim; Mirinae Seo; Woo Kyung Moon Journal: Eur Radiol Date: 2013-10-05 Impact factor: 5.315
Authors: Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: E C Inwald; M Klinkhammer-Schalke; F Hofstädter; F Zeman; M Koller; M Gerstenhauer; O Ortmann Journal: Breast Cancer Res Treat Date: 2013-05-16 Impact factor: 4.872
Authors: Kristen A Wangerin; Mark Muzi; Lanell M Peterson; Hannah M Linden; Alena Novakova; David A Mankoff; Paul E Kinahan Journal: Phys Med Biol Date: 2017-02-13 Impact factor: 3.609
Authors: Francesca Gallivanone; Marta Maria Panzeri; Carla Canevari; Claudio Losio; Luigi Gianolli; Francesco De Cobelli; Isabella Castiglioni Journal: MAGMA Date: 2017-02-28 Impact factor: 2.310